Mohammed Aldhaeefi, Hisham A Badreldin, Faisal Alsuwayyid, Tariq Alqahtani, Omar Alshaya, Majed S Al Yami, Khalid Bin Saleh, Shmeylan A Al Harbi, Abdulrahman I Alshaya
In recent years, anticoagulant and antiplatelet use have increased over the past years for the prevention and treatment of several cardiovascular conditions. Due to the rising use of antithrombotic medications and the complexity of specific clinical cases requiring such therapies, bleeding remains the primary concern among patients using antithrombotics. Direct oral anticoagulants (DOACs) include rivaroxaban, apixaban, edoxaban, and betrixaban. Direct thrombin inhibitors (DTIs) include argatroban, bivalirudin, and dabigatran...
February 11, 2023: Pharmacy (Basel, Switzerland)